Menu
https://www.investing.com/news/company-news/cvrx-director-slattery-buys-24300-in-company-stock-93CH-3574791
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX .
Insider Buying Alert: President & CEO Kevin Hykes Acquires 30,000 Shares of CVRx Inc (CVRX)
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The Centers Jetzt den vollständigen Artikel lesen
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44 th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com . About CVRx, Inc. CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body''s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.
CVRx Inc (CVRX) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amid Rising Expenses
Q2 2024 CVRx Inc Earnings Call Transcript
CVRx (NASDAQ: CVRX ) just reported results for the second quarter of 2024. CVRx reported earnings per share of -65 cents. This was below the analyst estimate for EPS of -55 cents. The company reported revenue of $11.81 million. This was 0.14% better than the analyst estimate for revenue of $11.79 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post CVRX Stock Earnings: CVRx Misses EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .
